Skip to main content

In new breakthrough, CRISPR tools target RNA to tackle dementia

CRISPR gene editing takes another big step forward, targeting RNA

Since it was first demonstrated in 2007, the gene-editing tool CRISPR/Cas9 has been used to edit DNA in an attempt to make organisms like drought-resistant crops and disease-resistant cattle. In November, the technology was even used in an attempt to treat a man with a serious inherited disease.

Now a team of researchers from the Salk Institute have identified a new family of CRISPR enzymes that target RNA instead of DNA, and used the tool to address protein imbalance in cells isolated from a person suffering from dementia.

“RNA ‘messages’ are key mediators of many biological processes,” Patrick Hsu, a Salk biology fellow who led the study, told Digital Trends. “They are the dynamic counterpart to comparatively static DNA sequences. In many diseases these RNA messages are out of balance, so the ability to target them directly and modulate them in a robust and specific way will be a great complement to DNA editing.”

Hsu continued, “Our goal was to explore the natural diversity of CRISPR systems throughout microbial life to find an RNA-targeting enzyme that would be highly robust and specific in human cells.”

Hsu admitted that the success rate for a project with such a broad scope was “generally quite low,” and that a few additional requirements made their effort even more complex. For one, they were determined to find a small CRISPR variant that could deliver RNA virally to parts of the brain — a function inaccessible to tools like Cas9. And the tool needed to be more flexible and efficient than today’s gold-standard RNA targeting technology.

To find their desired tool, Hsu and his colleagues first created a computational program that combed bacterial DNA databases, looking for the patterns of repeating DNA that signal a CRISPR system, and identified a family of RNA-targeting enzymes that they named Cas13d. They then specified their search in the Cas13d family for the version most relevant for use in human cells and landed on a gut bacterium called Ruminococcus flavefaciens XPD3002, or CasRx.

The researchers engineered CasRx to function in human cells and address a form of dementia called neurodegenerative disorder FTD. To do so, they packaged the tool into a virus and delivered it to neurons that were cultured from stem cells of an FTD patient. In a study published this week in the journal Cell, CasRx showed 80 percent effectiveness in rebalancing tau proteins, which are implicated in variants of dementia, including Alzheimer’s disease.

“This tool will be very useful for studying RNA biology in the near term and hopefully for treating RNA-related diseases in the future,” Hsu said. “Gene editing leads to changes in a genome sequence through DNA cuts and its effects are permanent in an edited cell … RNA-targeting with CasRx can be used to generate transient or graded changes without inducing DNA damage, such as to restore RNA levels to a healthy state.”

Editors' Recommendations

Dyllan Furness
Dyllan Furness is a freelance writer from Florida. He covers strange science and emerging tech for Digital Trends, focusing…
New startup promises ‘world’s first’ CRISPR-powered disease detection
CRISPR gene-editing technology

The Mammoth CRISPR Platform

Over the past few years, the gene-editing tool CRISPR has breathed new life into the field of genetics. Suddenly, genetic engineering was deemed both simple and efficient. CRISPR has been used to make specific tweaks to the genomes of myriad plants and animals, editing things like horns out of cattle and disease-resistance into crops.

Read more
CRISPR gene editing may have just become a whole lot more accurate
mcgill crispr 90 percent breakthrough wr 6 8 17

CRISPR gene editing is an enormously exciting area for molecular biologists, opening up new opportunities when it comes to editing DNA to fight back against a wide range of medical conditions. Heck, it’s so versatile that it can even be used to encode a GIF into the DNA of a virus, demonstrating how it is possible to capture complex information in living bacteria.

If CRISPR (clustered regularly interspaced short palindronic repeats) wasn’t already exciting enough, however, it could be about to become even more of a highly prized tool in the hands of researchers. At McGill University in Montreal, researchers in Uri David Akavia’s team have demonstrated CRISPR’s best success rate yet: managing to repair mutations in 90 percent of target cells.

Read more
With CRISPR, geneticists have a powerful new weapon in the battle against ALS
crispr als treatment gettyimages 713768585

For many people today, amyotrophic lateral sclerosis, aka ALS or Lou Gehrig's disease, is most commonly linked with both the fundraising Ice Bucket Challenge and one its most famous patients, the physicist Stephen Hawking. However, it could soon have a brand-new distinction -- the next disease to be treatable using CRISPR-Cas9 gene-editing technology.

In work carried out by researchers at University of California, Berkeley, scientists have been able to disable the defective gene that triggers ALS in mice. While they didn’t get rid of the disease permanently, the treatment did extend the mice's life span by 25 percent. The therapy delayed the onset of the muscle-wasting symptoms that characterize ALS, which ultimately become fatal when they spread to the muscles which control breathing.

Read more